Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Jyoti Patel

TitleProfessor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology/Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Jelinek MJ, Armstrong SA, Patel JD, Subramaniam DS. Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy. Clin Lung Cancer. 2019 Aug 26. PMID: 31542322.
      View in: PubMed
    2. Gadgeel SM, Lukas RV, Goldschmidt J, Conkling P, Park K, Cortinovis D, de Marinis F, Rittmeyer A, Patel JD, von Pawel J, O'Hear C, Lai C, Hu S, Ballinger M, Sandler A, Gandhi M, Fehrenbacher L. Atezolizumab in patients with advanced non-small cell lung cancer and history of asymptomatic, treated brain metastases: Exploratory analyses of the phase III OAK study. Lung Cancer. 2019 02; 128:105-112. PMID: 30642441.
      View in: PubMed
    3. Panou V, Gadiraju M, Wolin A, Weipert CM, Skarda E, Husain AN, Patel JD, Rose B, Zhang SR, Weatherly M, Nelakuditi V, Knight Johnson A, Helgeson M, Fischer D, Desai A, Sulai N, Ritterhouse L, Røe OD, Turaga KK, Huo D, Segal J, Kadri S, Li Z, Kindler HL, Churpek JE. Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant Mesothelioma. J Clin Oncol. 2018 10 01; 36(28):2863-2871. PMID: 30113886.
      View in: PubMed
    4. Patel JD, Chmura SJ. Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer? Cancer. 2018 07 15; 124(14):2878-2880. PMID: 29906817.
      View in: PubMed
    5. Patel JD, Paz-Ares L, Zinner RG, Barlesi F, Koustenis AG, Obasaju CK. Pemetrexed Continuation Maintenance Phase 3 Trials in Nonsquamous, Non-Small-Cell Lung Cancer: Focus on 2-Year Overall Survival and Continuum of Care. Clin Lung Cancer. 2018 11; 19(6):e823-e830. PMID: 30369427.
      View in: PubMed
    6. Luke JJ, Lemons JM, Karrison TG, Pitroda SP, Melotek JM, Zha Y, Al-Hallaq HA, Arina A, Khodarev NN, Janisch L, Chang P, Patel JD, Fleming GF, Moroney J, Sharma MR, White JR, Ratain MJ, Gajewski TF, Weichselbaum RR, Chmura SJ. Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors. J Clin Oncol. 2018 06 01; 36(16):1611-1618. PMID: 29437535.
      View in: PubMed
    7. Shah S, Wood K, Labadie B, Won B, Brisson R, Karrison T, Hensing T, Kozloff M, Bao R, Patel JD, Luke JJ. Clinical and molecular features of innate and acquired resistance to anti-PD-1/PD-L1 therapy in lung cancer. Oncotarget. 2018 Jan 12; 9(4):4375-4384. PMID: 29435109.
      View in: PubMed
    8. Stoy SP, Segal JP, Mueller J, Furtado LV, Vokes EE, Patel JD, Murgu S. Feasibility of Endobronchial Ultrasound-guided Transbronchial Needle Aspiration Cytology Specimens for Next Generation Sequencing in Non-small-cell Lung Cancer. Clin Lung Cancer. 2018 05; 19(3):230-238.e2. PMID: 29277564.
      View in: PubMed
    9. Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, Patel JD, Sborov MD, McDermott SR, Perez-Soler R, Traynor AM, Butts C, Evans T, Shafqat A, Chapman AE, Kasbari SS, Horn L, Ramalingam SS, Schiller JH. Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): an open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2017 12; 18(12):1610-1623. PMID: 29129443.
      View in: PubMed
    10. Peters S, Gettinger S, Johnson ML, Jänne PA, Garassino MC, Christoph D, Toh CK, Rizvi NA, Chaft JE, Carcereny Costa E, Patel JD, Chow LQM, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd FA, Kurata T, Li Z, Qiu J, Kowanetz M, Mocci S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). J Clin Oncol. 2017 Aug 20; 35(24):2781-2789. PMID: 28609226.
      View in: PubMed
    11. Soo RA, Stone ECA, Cummings KM, Jett JR, Field JK, Groen HJM, Mulshine JL, Yatabe Y, Bubendorf L, Dacic S, Rami-Porta R, Detterbeck FC, Lim E, Asamura H, Donington J, Wakelee HA, Wu YL, Higgins K, Senan S, Solomon B, Kim DW, Johnson M, Yang JCH, Sequist LV, Shaw AT, Ahn MJ, Costa DB, Patel JD, Horn L, Gettinger S, Peters S, Wynes MW, Faivre-Finn C, Rudin CM, Tsao A, Baas P, Kelly RJ, Leighl NB, Scagliotti GV, Gandara DR, Hirsch FR, Spigel DR. Scientific Advances in Thoracic Oncology 2016. J Thorac Oncol. 2017 08; 12(8):1183-1209. PMID: 28579481.
      View in: PubMed
    12. Gentzler RD, Mohindra NA, Hanna N, Chae YK, Jalal SI, Hall R, Villaflor VM, Reckamp KL, Koczywas M, Sullivan D, Wood L, Patel JD. Carboplatin/nab-Paclitaxel and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC): Phase 1 Results. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):236. PMID: 28587008.
      View in: PubMed
    13. Ni L, Koshy M, Connell PP, Hubert G, Vokes EE, Patel JD, Hoffman P, Al-Hallaq HA, Malik R. Impact of Cardiac Dose on Cardiac Events and Survival in Unresectable Lung Cancer Patients. Int J Radiat Oncol Biol Phys. 2017 May 01; 98(1):247. PMID: 28587036.
      View in: PubMed
    14. Winkfield KM, Flowers CR, Patel JD, Rodriguez G, Robinson P, Agarwal A, Pierce L, Brawley OW, Mitchell EP, Head-Smith KT, Wollins DS, Hayes DF. American Society of Clinical Oncology Strategic Plan for Increasing Racial and Ethnic Diversity in the Oncology Workforce. J Clin Oncol. 2017 Aug 01; 35(22):2576-2579. PMID: 28459634.
      View in: PubMed
    15. Wakelee H, Patel JD, Heist R, Balmanoukian A, Besse B, Felip E, Carcereny Costa E, Chow LQ, Koczywas M, Garassino MC, Christoph D, Toh CK, Johnson ML, Chaft J, Kurata T, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger SN, Peters S. ORAL01.04: Phase II Trial of Atezolizumab for Patients with PD-L1-Selected Advanced NSCLC (BIRCH): Updated Efficacy and Exploratory Biomarker Results: Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S251-S252. PMID: 27969443.
      View in: PubMed
    16. Shah S, Wood K, Brisson R, Karrison T, Hensing T, Luke JJ, Patel JD. PS01.63: Clinical Characteristics of Acquired Resistance with Anti-PD-1/PD-L1 in Non-Small Cell Lung Cancer (NSCLC): Topic: Medical Oncology. J Thorac Oncol. 2016 Nov; 11(11S):S310. PMID: 27969530.
      View in: PubMed
    17. Langer CJ, Socinski MA, Patel JD, Sandler AB, Schiller JH, Leon L, Hazard SJ, Ramalingam SS. Isolating the Role of Bevacizumab in Elderly Patients With Previously Untreated Nonsquamous Non-Small Cell Lung Cancer: Secondary Analyses of the ECOG 4599 and PointBreak Trials. Am J Clin Oncol. 2016 10; 39(5):441-7. PMID: 25628268.
      View in: PubMed
    18. Bahcall M, Sim T, Paweletz CP, Patel JD, Alden RS, Kuang Y, Sacher AG, Kim ND, Lydon CA, Awad MM, Jaklitsch MT, Sholl LM, Jänne PA, Oxnard GR. Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer. Cancer Discov. 2016 12; 6(12):1334-1341. PMID: 27694386.
      View in: PubMed
    19. Chen LF, Patel JD, Lukas RV. Advances in brain metastases presented at the American Society of Clinical Oncology 2016 Annual Meeting: Part II. Future Oncol. 2016 Dec; 12(23):2669-2672. PMID: 27605123.
      View in: PubMed
    20. Chen LF, Patel JD, Lukas RV. Advances in brain metastases presented at the American Society of Clinical Oncology 2016 Annual Meeting: Part I. Future Oncol. 2016 Nov; 12(22):2535-2538. PMID: 27595336.
      View in: PubMed
    21. Sanborn RE, Patel JD, Masters GA, Jayaram N, Stephens A, Guarino M, Misleh J, Wu J, Hanna N. A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113. Cancer. 2017 01 01; 123(2):303-311. PMID: 27583688.
      View in: PubMed
    22. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling T, Dobelbower M, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Swanson SJ, Stevenson J, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. J Natl Compr Canc Netw. 2016 07; 14(7):825-36. PMID: 27407123.
      View in: PubMed
    23. Patel JD, Pereira JR, Chen J, Liu J, Guba SC, John WJ, Orlando M, Scagliotti G, Bonomi PD. Relationship between efficacy outcomes and weight gain during treatment of advanced, non-squamous, non-small-cell lung cancer patients. Ann Oncol. 2016 08; 27(8):1612-9. PMID: 27217544.
      View in: PubMed
    24. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Dilling TJ, Dobelbower MC, Govindan R, Hennon M, Horn L, Jahan TM, Komaki R, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Schild SE, Shapiro TA, Sharma N, Stevenson J, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. J Natl Compr Canc Netw. 2016 03; 14(3):255-64. PMID: 26957612.
      View in: PubMed
    25. Rajaram R, Paruch JL, Mohanty S, Holl JL, Bilimoria KY, Ko CY, Winchester DP, Patel JD, DeCamp MM. Patterns and Predictors of Chemotherapy Use for Resected Non-Small Cell Lung Cancer. Ann Thorac Surg. 2016 Feb; 101(2):533-40. PMID: 26507427.
      View in: PubMed
    26. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Dobelbower MC, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild SE, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-Small Cell Lung Cancer, Version 6.2015. J Natl Compr Canc Netw. 2015 May; 13(5):515-24. PMID: 25964637.
      View in: PubMed
    27. Johnson ML, Yu HA, Hart EM, Weitner BB, Rademaker AW, Patel JD, Kris MG, Riely GJ. Phase I/II Study of HSP90 Inhibitor AUY922 and Erlotinib for EGFR-Mutant Lung Cancer With Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors. J Clin Oncol. 2015 May 20; 33(15):1666-73. PMID: 25870087.
      View in: PubMed
    28. Patel JD. Overcoming perceived hurdles in lung cancer screening: the low risk of complications of image-guided transthoracic needle biopsy. J Oncol Pract. 2015 May; 11(3):e360-2. PMID: 25804985.
      View in: PubMed
    29. Katzen JB, Raparia K, Agrawal R, Patel JD, Rademaker A, Varga J, Dematte JE. Early stage lung cancer detection in systemic sclerosis does not portend survival benefit: a cross sectional study. PLoS One. 2015; 10(2):e0117829. PMID: 25689302.
      View in: PubMed
    30. Spigel DR, Patel JD, Reynolds CH, Garon EB, Hermann RC, Govindan R, Olsen MR, Winfree KB, Chen J, Liu J, Guba SC, Socinski MA, Bonomi P. Quality of life analyses from the randomized, open-label, phase III PointBreak study of pemetrexed-carboplatin-bevacizumab followed by maintenance pemetrexed-bevacizumab versus paclitaxel-carboplatin-bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Thorac Oncol. 2015 Feb; 10(2):353-9. PMID: 25611228.
      View in: PubMed
    31. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. PMID: 25605863.
      View in: PubMed
    32. Ettinger DS, Wood DE, Akerley W, Bazhenova LA, Borghaei H, Camidge DR, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Dilling TJ, Govindan R, Grannis FW, Horn L, Jahan TM, Komaki R, Kris MG, Krug LM, Lackner RP, Lanuti M, Lilenbaum R, Lin J, Loo BW, Martins R, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Schild S, Shapiro TA, Swanson SJ, Tauer K, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 1.2015. J Natl Compr Canc Netw. 2014 Dec; 12(12):1738-61. PMID: 25505215.
      View in: PubMed
    33. Reynolds CH, Patel JD, Garon EB, Olsen MR, Bonomi P, Govindan R, Pennella EJ, Liu J, Guba SC, Li S, Spigel DR, Hermann RC, Socinski MA, Obasaju CK. Exploratory Subset Analysis of African Americans From the PointBreak Study: Pemetrexed-Carboplatin-Bevacizumab Followed by Maintenance Pemetrexed-Bevacizumab Versus Paclitaxel-Carboplatin-Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB/IV Nonsquamous Non-Small-Cell Lung Cancer. Clin Lung Cancer. 2015 May; 16(3):200-8. PMID: 25516338.
      View in: PubMed
    34. Schink JC, Trosman JR, Weldon CB, Siziopikou KP, Tsongalis GJ, Rademaker AW, Patel JD, Benson AB, Perez EA, Gradishar WJ. Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers. J Natl Cancer Inst. 2014 Oct; 106(10). PMID: 25217578.
      View in: PubMed
    35. Gentzler RD, Yentz SE, Johnson ML, Rademaker AW, Patel JD. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria. Cancer. 2014 Dec 15; 120(24):3853-8. PMID: 25155290.
      View in: PubMed
    36. Munk MR, Fernandes J, Mets M, Patel JD, Johnson ML, Jampol LM. Reversible nyctalopia and retinopathy in a patient with metastatic cancer treated with anti-heat shock protein 90 therapy. JAMA Ophthalmol. 2014 Jul; 132(7):899-901. PMID: 25010175.
      View in: PubMed
    37. Gentzler RD, Patel JD. Optimal first-line and maintenance treatments for advanced-stage nonsquamous non-small cell lung cancer. J Natl Compr Canc Netw. 2014 Jun; 12(6):889-97. PMID: 24925199.
      View in: PubMed
    38. Villa C, Cagle PT, Johnson M, Patel JD, Yeldandi AV, Raj R, DeCamp MM, Raparia K. Correlation of EGFR mutation status with predominant histologic subtype of adenocarcinoma according to the new lung adenocarcinoma classification of the International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society. Arch Pathol Lab Med. 2014 Oct; 138(10):1353-7. PMID: 24571650.
      View in: PubMed
    39. Gentzler RD, Patel JD. Maintenance treatment after induction therapy in non-small cell lung cancer: latest evidence and clinical implications. Ther Adv Med Oncol. 2014 Jan; 6(1):4-15. PMID: 24381656.
      View in: PubMed
    40. Johnson ML, Patel JD. Chemotherapy and targeted therapeutics as maintenance of response in advanced non-small cell lung cancer. Semin Oncol. 2014 Feb; 41(1):93-100. PMID: 24565583.
      View in: PubMed
    41. Patel JD, Krilov L, Adams S, Aghajanian C, Basch E, Brose MS, Carroll WL, de Lima M, Gilbert MR, Kris MG, Marshall JL, Masters GA, O'Day SJ, Polite B, Schwartz GK, Sharma S, Thompson I, Vogelzang NJ, Roth BJ. Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2014 Jan 10; 32(2):129-60. PMID: 24327669.
      View in: PubMed
    42. Gentzler RD, Yentz SE, Patel JD. Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use. Curr Treat Options Oncol. 2013 Dec; 14(4):595-609. PMID: 23990213.
      View in: PubMed
    43. Brahmer JR, Lee JW, Traynor AM, Hidalgo MM, Kolesar JM, Siegfried JM, Guaglianone PP, Patel JD, Keppen MD, Schiller JH. Dosing to rash: a phase II trial of the first-line erlotinib for patients with advanced non-small-cell lung cancer an Eastern Cooperative Oncology Group Study (E3503). Eur J Cancer. 2014 Jan; 50(2):302-8. PMID: 24246704.
      View in: PubMed
    44. Patel JD, Socinski MA, Garon EB, Reynolds CH, Spigel DR, Olsen MR, Hermann RC, Jotte RM, Beck T, Richards DA, Guba SC, Liu J, Frimodt-Moller B, John WJ, Obasaju CK, Pennella EJ, Bonomi P, Govindan R. PointBreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. J Clin Oncol. 2013 Dec 01; 31(34):4349-57. PMID: 24145346.
      View in: PubMed
    45. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):645-53; quiz 653. PMID: 23744864.
      View in: PubMed
    46. Ettinger DS, Riely GJ, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Grant SC, Horn L, Jahan TM, Komaki R, Kong FM, Kris MG, Krug LM, Lackner RP, Lennes IT, Loo BW, Martins R, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Rohren E, Shapiro TA, Swanson SJ, Tauer K, Wood DE, Yang SC, Gregory K, Hughes M. Thymomas and thymic carcinomas: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2013 May 01; 11(5):562-76. PMID: 23667206.
      View in: PubMed
    47. Raparia K, Villa C, DeCamp MM, Patel JD, Mehta MP. Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. Arch Pathol Lab Med. 2013 Apr; 137(4):481-91. PMID: 23544937.
      View in: PubMed
    48. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow LQ, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan T, Koczywas M, Loo BW, Merritt RE, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC, Gregory K, Hughes M. Small cell lung cancer. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):78-98. PMID: 23307984.
      View in: PubMed
    49. Roth BJ, Krilov L, Adams S, Aghajanian CA, Bach P, Braiteh F, Brose MS, Ellis LM, Erba H, George DJ, Gilbert MR, Jacobson JO, Larsen EC, Lichtman SM, Partridge AH, Patel JD, Quinn DI, Robison LL, von Roenn JH, Samlowski W, Schwartz GK, Vogelzang NJ. Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. J Clin Oncol. 2013 Jan 01; 31(1):131-61. PMID: 23213095.
      View in: PubMed
    50. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pinder-Schenck MC, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC, Hughes M, Gregory KM. Non-small cell lung cancer. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1236-71. PMID: 23054877.
      View in: PubMed
    51. Magasi S, Mallick R, Kaiser K, Patel JD, Lad T, Johnson ML, Kaplan EH, Cella D. Importance and relevance of pulmonary symptoms among patients receiving second- and third-line treatment for advanced non-small-cell lung cancer: support for the content validity of the 4-item Pulmonary Symptom Index. Clin Lung Cancer. 2013 May; 14(3):245-53. PMID: 23036663.
      View in: PubMed
    52. Kelly K, Azzoli CG, Zatloukal P, Albert I, Jiang PY, Bodkin D, Pereira JR, Juhász E, Iannotti NO, Weems G, Koutsoukos T, Patel JD. Randomized phase 2b study of pralatrexate versus erlotinib in patients with stage IIIB/IV non-small-cell lung cancer (NSCLC) after failure of prior platinum-based therapy. J Thorac Oncol. 2012 Jun; 7(6):1041-8. PMID: 22534814.
      View in: PubMed
    53. Ettinger DS, Akerley W, Borghaei H, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Horn L, Jahan TM, Jahanzeb M, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Lennes IT, Loo BW, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Schenck MP, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Malignant pleural mesothelioma. J Natl Compr Canc Netw. 2012 Jan; 10(1):26-41. PMID: 22223867.
      View in: PubMed
    54. Vogelzang NJ, Benowitz SI, Adams S, Aghajanian C, Chang SM, Dreyer ZE, Janne PA, Ko AH, Masters GA, Odenike O, Patel JD, Roth BJ, Samlowski WE, Seidman AD, Tap WD, Temel JS, Von Roenn JH, Kris MG. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology. J Clin Oncol. 2012 Jan 01; 30(1):88-109. PMID: 22147736.
      View in: PubMed
    55. Azzoli CG, Patel JD, Krug LM, Miller V, James L, Kris MG, Ginsberg M, Subzwari S, Tyson L, Dunne M, May J, Huntington M, Saunders M, Sirotnak FM. Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial. J Thorac Oncol. 2011 Nov; 6(11):1915-22. PMID: 21841501.
      View in: PubMed
    56. Kalemkerian GP, Akerley W, Bogner P, Borghaei H, Chow L, Downey RJ, Gandhi L, Ganti AK, Govindan R, Grecula JC, Hayman J, Heist RS, Horn L, Jahan TM, Koczywas M, Moran CA, Niell HB, O'Malley J, Patel JD, Ready N, Rudin CM, Williams CC. Small cell lung cancer. J Natl Compr Canc Netw. 2011 Oct; 9(10):1086-113. PMID: 21975911.
      View in: PubMed
    57. Kulesza P, Ramchandran K, Patel JD. Emerging concepts in the pathology and molecular biology of advanced non-small cell lung cancer. Am J Clin Pathol. 2011 Aug; 136(2):228-38. PMID: 21757595.
      View in: PubMed
    58. Patel JD, Galsky MD, Chagpar AB, Pyle D, Loehrer PJ. Role of American Society of Clinical Oncology in low- and middle-income countries. J Clin Oncol. 2011 Aug 01; 29(22):3097-102. PMID: 21709190.
      View in: PubMed
    59. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Govindan R, Grannis FW, Jahan T, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Swanson SJ, Wood DE, Yang SC. Thymic malignancies. J Natl Compr Canc Netw. 2010 Nov; 8(11):1302-15. PMID: 21081786.
      View in: PubMed
    60. Ettinger DS, Akerley W, Bepler G, Blum MG, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Ganti AK, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Johnson DH, Kessinger A, Komaki R, Kong FM, Kris MG, Krug LM, Le QT, Lennes IT, Martins R, O'Malley J, Osarogiagbon RU, Otterson GA, Patel JD, Pisters KM, Reckamp K, Riely GJ, Rohren E, Simon GR, Swanson SJ, Wood DE, Yang SC. Non-small cell lung cancer. J Natl Compr Canc Netw. 2010 Jul; 8(7):740-801. PMID: 20679538.
      View in: PubMed
    61. Eilers RE, Gandhi M, Patel JD, Mulcahy MF, Agulnik M, Hensing T, Lacouture ME. Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy. J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53. PMID: 20007525.
      View in: PubMed
    62. Ramchandran K, Patel JD. Sex differences in susceptibility to carcinogens. Semin Oncol. 2009 Dec; 36(6):516-23. PMID: 19995643.
      View in: PubMed
    63. Patel JD. Lung cancer: a biologically different disease in women? Womens Health (Lond). 2009 Nov; 5(6):685-91. PMID: 19863471.
      View in: PubMed
    64. Patel JD, Bonomi P, Socinski MA, Govindan R, Hong S, Obasaju C, Pennella EJ, Girvan AC, Guba SC. Treatment rationale and study design for the pointbreak study: a randomized, open-label phase III study of pemetrexed/carboplatin/bevacizumab followed by maintenance pemetrexed/bevacizumab versus paclitaxel/carboplatin/bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small-cell lung cancer. Clin Lung Cancer. 2009 Jul; 10(4):252-6. PMID: 19632943.
      View in: PubMed
    65. Patel JD, Hensing TA, Rademaker A, Hart EM, Blum MG, Milton DT, Bonomi PD. Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer. J Clin Oncol. 2009 Jul 10; 27(20):3284-9. PMID: 19433684.
      View in: PubMed
    66. Nonzee NJ, Dandade NA, Patel U, Markossian T, Agulnik M, Argiris A, Patel JD, Kern RC, Munshi HG, Calhoun EA, Bennett CL. Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer. 2008 Sep 15; 113(6):1446-52. PMID: 18683883.
      View in: PubMed
    67. Cella DF, Patel JD. Improving health-related quality of life in non-small-cell lung cancer with current treatment options. Clin Lung Cancer. 2008 Jul; 9(4):206-12. PMID: 18650167.
      View in: PubMed
    68. Abraham T, Rademaker A, Ortiz S, Bennett CL, Richey E, Nonzee NJ, West DP, Patel JD, Lacouture ME. Economic impact associated with the management of dermatologic adverse drug reactions (dADRs) induced by EGFR inhibitors (EGFRIs) in lung cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):19094. PMID: 27947833.
      View in: PubMed
    69. Patel JD, Hensing TA, Rademaker F, Hart E, Obasaju CK, Treat J, Milton D, Bonomi PD. Pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab as first-line therapy for advanced non-squamous non-small cell lung cancer (NSCLC). J Clin Oncol. 2008 May 20; 26(15_suppl):8044. PMID: 27949033.
      View in: PubMed
    70. Fidler MJ, Argiris A, Patel JD, Johnson DH, Sandler A, Villaflor VM, Coon J, Buckingham L, Kaiser K, Basu S, Bonomi P. The potential predictive value of cyclooxygenase-2 expression and increased risk of gastrointestinal hemorrhage in advanced non-small cell lung cancer patients treated with erlotinib and celecoxib. Clin Cancer Res. 2008 Apr 01; 14(7):2088-94. PMID: 18381949.
      View in: PubMed
    71. Miller VA, Riely GJ, Zakowski MF, Li AR, Patel JD, Heelan RT, Kris MG, Sandler AB, Carbone DP, Tsao A, Herbst RS, Heller G, Ladanyi M, Pao W, Johnson DH. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol. 2008 Mar 20; 26(9):1472-8. PMID: 18349398.
      View in: PubMed
    72. Ettinger DS, Akerley W, Bepler G, Chang A, Cheney RT, Chirieac LR, D'Amico TA, Demmy TL, Feigenberg SJ, Figlin RA, Govindan R, Grannis FW, Jahan T, Jahanzeb M, Kessinger A, Komaki R, Kris MG, Langer CJ, Le QT, Martins R, Otterson GA, Patel JD, Robert F, Sugarbaker DJ, Wood DE. Non-small cell lung cancer. J Natl Compr Canc Netw. 2008 Mar; 6(3):228-69. PMID: 18377844.
      View in: PubMed
    73. Patel JD. Epidermal growth factor receptor pathway targeted therapy in patients with aerodigestive malignancies. Curr Opin Oncol. 2006 Nov; 18(6):609-14. PMID: 16988582.
      View in: PubMed
    74. Kris MG, Sandler A, Miller VA, Zakowski MF, Pao W, Tsao A, Patel JD, Johnson DH, Carbone DP. EGFR and KRAS mutations in patients with bronchioloalveolar carcinoma treated with erlotinib in a phase II multicenter trial. J Clin Oncol. 2005 Jun; 23(16_suppl):7029. PMID: 27944467.
      View in: PubMed
    75. Patel JD, Gray RG, Stewart JA, Skinner HG, Schiller JH. Tamoxifen does not reduce the risk of lung cancer in women. J Clin Oncol. 2005 Jun; 23(16_suppl):7212. PMID: 27944681.
      View in: PubMed
    76. Patel JD. Lung cancer in women. J Clin Oncol. 2005 May 10; 23(14):3212-8. PMID: 15886308.
      View in: PubMed
    77. Halpin RJ, Bendok BR, Sato KT, Liu JC, Patel JD, Rosen ST. Combination treatment of vertebral metastases using image-guided percutaneous radiofrequency ablation and vertebroplasty: a case report. Surg Neurol. 2005 May; 63(5):469-74; discussion 474-5. PMID: 15883077.
      View in: PubMed
    78. Patel JD. Role of epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of bronchoalveolar carcinoma. Clin Lung Cancer. 2004 Dec; 6 Suppl 1:S43-7. PMID: 15638957.
      View in: PubMed
    79. Patel JD, Blum MG, Argiris A. Induction chemotherapy for resectable non-small-cell lung cancer. Oncology (Williston Park). 2004 Nov; 18(13):1591-602; discussion 1602-3, 1606, 1611-2. PMID: 15648293.
      View in: PubMed
    80. Kut V, Patel JD, Argiris A. Pemetrexed: a novel antifolate agent enters clinical practice. Expert Rev Anticancer Ther. 2004 Aug; 4(4):511-22. PMID: 15270656.
      View in: PubMed
    81. Patel JD, Pasche B, Argiris A. Targeting non-small cell lung cancer with epidermal growth factor tyrosine kinase inhibitors: where do we stand, where do we go. Crit Rev Oncol Hematol. 2004 Jun; 50(3):175-86. PMID: 15182824.
      View in: PubMed
    82. Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA. 2004 Apr 14; 291(14):1763-8. PMID: 15082704.
      View in: PubMed
    83. Patel JD, Krug LM, Azzoli CG, Gomez J, Kris MG, Miller VA. Targeting lethal minimal residual disease in small cell lung cancer. Semin Oncol. 2003 Feb; 30(1):79-85. PMID: 12635092.
      View in: PubMed
    84. Mason NA, Patel JD, Dressman JB, Shimp LA. Consumer vinegar test for determining calcium disintegration. Am J Hosp Pharm. 1992 Sep; 49(9):2218-22. PMID: 1524066.
      View in: PubMed
    85. Mehta P, Patel JD, Milder JE. Legionella micdadei (Pittsburgh pneumonia agent). Two infections with unusual clinical features. JAMA. 1983 Mar 25; 249(12):1620-3. PMID: 6338266.
      View in: PubMed
    Patel's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _